The incidence of Gram-negative bacteremia has increased in hematopoietic stem cell transplant (HSCT) recipients. We prospectively collected data from 13 Brazilian HSCT centers to characterize the epidemiology of bacteremia occurring early post transplant, and to identify factors associated with infection due to multi-drug-resistant (MDR) Gram-negative isolates. MDR was defined as an isolate with resistance to at least two of the following: third-or fourth-generation cephalosporins, carbapenems or piperacillin-tazobactam. Among 411 HSCT, fever occurred in 333, and 91 developed bacteremia (118 isolates): 47% owing to Gram-positive, 37% owing to Gram-negative, and 16% caused by Gram-positive and Gram-negative bacteria. Pseudomonas aeruginosa (22%), Klebsiella pneumoniae (19%) and Escherichia coli (17%) accounted for the majority of Gram-negative isolates, and 37% were MDR. These isolates were recovered from 20 patients, representing 5% of all 411 HSCT and 22% of the episodes with bacteremia. By multivariate analysis, treatment with third-generation cephalosporins (odds ratio (OR) 10.65, 95% confidence interval (CI) 3. 75-30.27) and being at one of the hospitals (OR 9.47, 95% CI 2.60-34.40) were associated with infection due to MDR Gram-negative isolates. These findings may have important clinical implications in the decision of giving prophylaxis and selecting the empiric antibiotic regimen.
Bacteremia remains an important cause of infection among hematopoietic stem cell transplant (HSCT) recipients, occurring in up to 30% of febrile neutropenic episodes during the early post-transplant period. 1 Over the past decade, Gram-positive bacteria accounted for the large majority of pathogens causing bacteremia during neutropenia. 2, 3 However, recent studies have reported a reemergence of Gram-negative bacteria in neutropenic cancer patients. Haupt et al. 4 observed a 3.4% increase per year in Gram-negative bacteremia among children treated for solid tumors from 1985 to 1996. Collin et al. 1 reported a decrease in the ratio of Gram-positive/Gram-negative, from 2.7 to 1.3 in bacteremic HSCT recipients. A recent trial conducted by the EORTC-IATG showed an increase of Gramnegative bacteremia in neutropenic patients, from 6.5 to 12% (Po0.001). 5 The reasons for these epidemiologic changes are not clear.
In recent years, a notable increase in antibiotic resistance among Gram-negative bacteria has been reported, especially in critically ill patients. 6 These infections are associated with increased morbidity, mortality, and costs. 7, 8 In our institution, we observed that 4.5% of 245 bacteremias occurring during neutropenia in HSCT recipients were caused by multi-drug-resistant (MDR) Gramnegative bacteria, representing an increase from 1.7 cases per 1000 days of neutropenia between 1994 and 2002 to 8.6 cases per 1000 days of neutropenia in 2003. 9 Furthermore, MDR Gram-negative bacteremia was associated with a seven-fold increase in the risk of death by multivariate analysis. While epidemiologic studies conducted in Brazilian institutions suggest that infection owing to MDR Gram-negative bacteria is a great problem, [10] [11] [12] the magnitude of this problem in HSCT recipients is not known. The purpose of this study was to evaluate the epidemiology of bacteremia occurring during the period of neutropenia of Brazilian HSCT recipients, with a special emphasis on the prevalence, susceptibility profile and factors associated with MDR Gram-negative bacteremia.
Patients and methods
The study was conducted between 1 March and 30 November 2004 in 13 Brazilian HSCT centers located in 10 cities of the south, southeast and central regions of Brazil. All centers have an active program of HSCT (autologous and/or allogeneic), an automated blood culture system (BACTEC R or BacT/ALERT R ), and follow standard procedures for species identification and susceptibility tests of bacteria. 13 All HSCT recipients who developed neutropenia after the conditioning regimen were included in this cohort. The patients were followed from day zero until neutrophil engraftment or death. A standardized case report form was prospectively completed and sent electronically to the data management center. The case report form contained the following information: demographics, underlying disease and its status at the time of transplant (active disease vs in complete remission), type of transplant (autologous, allogeneic with myeloablative conditioning regimen, non-myeloablative, HLA-mismatched, unrelated), source of stem cells (peripheral blood, bone marrow, cord blood), conditioning regimen, antimicrobial prophylaxis, fever, empiric antibiotic regimen, classification of the febrile episode, documentation of infection, and if the patient developed bacteremia, species identification and susceptibility profile of the etiologic agent(s) of bacteremia. In addition, information on the total duration of neutropenia and the outcome were recorded.
The protocol for the management of neutropenia (including antimicrobial prophylaxis and therapy of febrile neutropenia) was followed according to standards of each center. Neutropenia was defined as a neutrophil count o500 cells Â 10 9 /l, and fever as an axillary temperature X37.81C. The febrile episodes were classified according to definitions of the Immunocompromised Host Society as fever of unknown origin (FUO), bacteremia, microbiologically documented infection without bacteremia, and clinically documented infection.
14 Breakthrough bacteremia was defined as an episode of bacteremia occurring 424 h after the initiation of empiric antibiotic therapy. A Gram-negative isolate that exhibited resistance to at least two antibiotics used in empirical therapy (third and fourthgeneration cephalosporins, carbapenems or piperacillintazobactam) was defined as MDR. Neutrophil engraftment was defined when three consecutive neutrophil counts were 4500 Â 10 6 /l. Data were entered by a web-based case report form, using the SPSS Enterprise Server 3.0 and SPSS Data Entry Builder 3.03 (SPSS Inc., Chicago, IL, USA). Categorical data were analyzed using w 2 or Fisher's exact tests, as appropriate, and continuous variables were compared using the Wilcoxon test. We performed univariate and multivariate analyses of factors associated with the development of fever and bacteremia due to MDR Gramnegative bacteria by comparing patients with and without these features. Variables significant at Po0.1 by univariate analysis were included in a multivariate model (backward and forward). Data were analyzed using the SPSS 11.0.1 software (SPSS Inc., Chicago, IL, USA).
Results
Patients' demographics and antimicrobial usage During the study period, 411 HSCT (225 allogeneic and 186 autologous) were performed in the 13 institutions. The median number of HSCT per center was 16 (range 9-114). Characteristics of the HSCT are shown in Table 1 . Among allogeneic HSCT, the most frequent underlying diseases were chronic myeloid leukemia (CML -75 patients, 33%) and acute myeloid leukemia (AML -44 patients, 20%). Among autologous HSCT, multiple myeloma (65 patients, 35%), Hodgkin's disease and non-Hodgkin's lymphoma (40 patients each, 21%) were the most frequent underlying diseases. The stem cell source was the peripheral blood in 252 (61%), bone marrow in 142 (35%) and cord blood in 17 (4%). The median age of patients was 32 (range 1-66 years) and 230 patients were men. Fifteen patients (seven autologous and eight allogeneic) underwent a second transplant.
Antibacterial prophylaxis was given to 138 patients (34%), mostly betalactam agents (51%) and quinolones (38%). Antifungal prophylaxis was given to 87% of patients, and fluconazole was the most frequently prescribed drug (83%). Fever occurred in 333 HSCT (81%). Patients receiving quinolone prophylaxis (odds ratio (OR) 0.15, 95% confidence interval (CI) 0.08-0.31, Po0.001) and recipients of non-myeloablative HSCT (OR 0.13, Table 2 , 59 Gram-positive and 59 Gramnegative isolates were recovered from blood cultures. Among Gram-negative bacteria, Pseudomonas aeruginosa (22%), Klebsiella pneumoniae (19%) and Escherichia coli (17%) accounted for the majority of isolates. Enterobacter species and Acinetobacter species accounted for 12 and 10% of Gram-negative bloodstream isolates, respectively. Twenty-two of the 59 Gram-negative isolates (37%) were MDR. These isolates were recovered from 20 patients, representing 5% of all 411 HSCT, 6% of the 333 febrile neutropenic episodes, and 22% of the episodes with bacteremia. The episodes of MDR Gram-negative bacteremia were distributed through 10 of the 13 centers, with a prevalence varying between 0 and 18%. The MDR Gramnegative isolates were: K. pneumoniae (6), P. aeruginosa (5), Enterobacter spp (3), E. coli (2), Burkholderia cepacia (2), Stenotrophomonas malthophilia (2), Acinetobacter spp (1) and Citrobacter freundii (1).
As shown in Table 3 , all MDR Gram-negative isolates were resistant to ceftazidime. E. coli and most K. pneumoniae isolates (four of five) remained susceptible to imipenem, whereas most P. aeruginosa isolates (four of five) were resistant to this antibiotic. Resistance to ciprofloxacin was observed in five of six MDR K. pneumoniae and four of five MDR P. aeruginosa. A high rate of resistance to amikacin was also observed. There was no apparent cluster of a specific MDR phenotype in any of the 13 institutions.
Risk factors for MDR-Gram-negative
Patients who received third generation cephalosporins either as prophylaxis or empirical therapy were more likely to develop infection due to MDR Gram-negative isolates (20 vs 3%, Po0.001), as were patients admitted to two of the 13 hospitals (18 vs 4%, P ¼ 0.02, and 15 vs 4%, P ¼ 0.02, respectively). By contrast, patients admitted to another center were less likely to have infection due to MDR Gram-negative isolates (1 vs 6%, P ¼ 0.02). By multivariate analysis, receipt of third generation cephalosporins (OR 10.65, 95% CI 3.75-30.27) and being at one of the hospitals (OR 9.47, 95% CI 2.60-34.40) were associated with infection due to MDR Gram-negative isolates (Table 4) . Interestingly, no patient admitted to this hospital had received third-generation cephalosporins.
We ran the same analysis of potential risk factors for infection due to MDR Gram-negative isolates excluding the 78 HSCT recipients who did not develop fever during neutropenia. Again, receipt of third-generation cephalosporins (20 vs 4%, P ¼ 0.001), and being at those two hospitals (33 vs 4%, P ¼ 0.001, and 21 vs 5%, P ¼ 0.01, respectively) were associated with infection due to MDR Gram-negative isolates. In addition, there was a trend for an association between use of quinolone as prophylaxis and MDR Gram-negative bacteremia (14 vs 5%, P ¼ 0.07). However, by multivariate analysis, receipt of third-generation cephalosporins (OR 9.69, 95% CI 3.29-28.56) and being at the same hospital as for the previous analysis 
(OR 10.02, 95% CI 2.64-38.03) were associated with infection due to MDR Gram-negative isolates.
Outcome and predictors of death Forty patients died during the neutropenic phase after HSCT (10%). Twenty-five (62%) of these 40 patients developed an infection that was attributed by the investigators as the cause of death. The death rate of patients with bacteremia due to MDR Gram-negative isolates was 20% (four of 20 patients), compared to 9% in the rest of the cohort (P ¼ 0.12). The MDR Gram-negative bacteria recovered from the blood of the four patients who died were E. coli (2 cases), K. pneumoniae and P. 
Discussion
Our study was the first collaborative effort involving different Brazilian institutions designed to collect prospective data on bacteremia among HSCT recipients. The participating transplant centers were selected among about 40 centers in Brazil, to target representative information on the epidemiology of these infections in different regions of Brazil. We used a web-based case-report form to facilitate the processes of entering data, generating queries and analyzing. The system enabled us to have immediate access to every case entered in the database, and to analyze all data once the database was cleared. We observed a 5% 
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Multi-drug-resistant isolates (22) K. pneumoniae ( overall incidence of bacteremia caused by MDR Gramnegative isolates, and identified two variables associated with this infection: receipt of third-generation cephalosporins and being at one of the 13 centers. In European and North-American series, Gram-positive bacteria contribute to the majority of bacteremias during febrile neutropenia, 3, 15, 16 but recent studies have suggested that the incidence of Gram-negative bacteremia is increasing.
1,2,17 A recent review from sequential EORTC trials of antibiotics in febrile neutropenia reported a resurgence of Gram-negative bacteremia, and in the period from 1993 to 2000, the incidence of Gram-negative and Gram-positive infections were approximately the same (12 and 13%, respectively). 5 In Brazil, a recently published single-center study showed that Gram-negative bacteria accounted for 51.9% of bloodstream infections in neutropenic cancer patients. 18 On the other hand, another study showed that Gram-positive bacteria accounted for 56% of 23 episodes of bacteremia among 68 febrile neutropenic children enrolled in a clinical trial. 19 Among HSCT recipients, data from a single center showed a predominance of Grampositive bacteria (64% of 36 episodes of bacteremia among 120 autologous HSCT recipients). 20 In the present study, Gram-positive bacteria accounted for 47% of episodes of bacteremia, whereas 37% were caused by Gram-negative bacteria, and 16% were mixed infections, but the number of bloodstream isolates was equal (59 isolates each). Despite the paucity of data, taken together these data suggest that the frequency of Gram-negative bacteremia is higher in Brazilian series compared to North American and European series. Although the reasons for these observations are not very clear, one possibility is that only 13% of our HSCT recipients received quinolone prophylaxis. The use of quinolones reduces Gram-negative bacteremia, 21 and has been regarded as one of the main reasons for the decrease in Gram-negative bacteremia among neutropenic patients observed in the northern hemisphere in the 1990s. However, some authors reported an increase in Gramnegative bacteremia despite use of quinolone prophylaxis. 22 The use of quinolone prophylaxis in the present study reduced by 85% the risk of developing fever. The other variable associated with a reduction in the risk of developing fever during the neutropenia was non-myeloablative HSCT. This type of transplant is typically associated with less-severe neutropenia and mucositis compared with myeloablative transplants. 23 As reported in most series, coagulase-negative staphylococci accounted for the majority of Gram-positive isolates (24% of the 118 bloodstream isolates and 49% of Grampositive isolates), although in lower proportion than that reported elsewhere. 3, 17, 24 Of note, S. aureus was the second most frequent agent of bacteremia (13 isolates, 23% of Gram-positive isolates and 11% of all bloodstream isolates), together with P. aeruginosa. This is in contrast to the low frequency of this agent in bloodstream infections of neutropenic patients from Europe and North America. [1] [2] [3] Interestingly, in another study at a Brazilian cancer center, S. aureus accounted for 12% of bloodstream isolates among neutropenic patients. 18 Among Gram-negative bacteria, P. aeruginosa, K. pneumoniae and E. coli were the most frequent agents of bacteremia. The susceptibility profile of Gram-negative isolates showed a significant proportion of MDR, according to our definition: 37% of Gram-negative bloodstream isolates were MDR. Drug resistance has become a great concern among patients with hematologic malignancies. Lang et al. 25 reported a greater proportion of resistant isolates in hematologic ward compared to the intensive care unit, and attributed it to a high density of antimicrobial use among hematologic patients. In our study, resistance was most frequently observed with K. pneumoniae (six out of 11 isolates), Enterobacter sp (three out of seven isolates), P. aeruginosa (five out of 13 isolates), and E. coli (two out of 10 isolates). These four agents accounted for 72% of MDR Gram-negative isolates. Among enterobacteria, the rates of extended-spectrum b-lactamases (ESBL) production were high (four of 11 K. pneumoniae and two of 10 E. coli), as was the rate of resistance of P. aeruginosa to thirdgeneration cephalosporins and carbapenems. This is in contrast with another study in HSCT recipients, 1 in which enterobacteria remained fully sensitive to most antimicrobial agents, and only 14% of P. aeruginosa isolates were resistant to ceftazidime and tobramicin. Conversely, Lang et al. 25 reported that 39, 74 and 88% of P. aeruginosa isolates were resistant to cefepime, imipenem and ciprofloxacin, respectively.
In the present study, previous exposure to thirdgeneration cephalosporins and belonging to one of the HSCT centers were associated with an increased risk for MDR Gram-negative bacteremia by multivariate analysis. The use of antimicrobials has been found to be related with acquisition of multi-resistant pathogens in similar studies. Spanik et al. 26 reported a higher incidence of MDR Gramnegative infections in neutropenic cancer patients who received third-generation cephalosporins as prophylaxis (41.2 vs 13.7%, Po0.01). The authors also reported that previous use of quinolones and other broad-spectrum antibiotics (second generation cephalosporins, aminoglycosides and imipenem) were more frequently associated with MDR Gram-negative infections. The use of quinolones has also been identified as a risk factor for P. aeruginosaproducing metallobetalactamase in a tertiary-care hospital in Brazil. 27 In the present study, we observed a trend to a higher incidence of infection due to MDR Gram-negative isolates in patients who received quinolone prophylaxis (14 vs 5%, P ¼ 0.07). By contrast, the use of thirdgeneration cephalosporins was strongly associated with bacteremia owing to MDR Gram-negative isolates. This is not surprising, since most of our MDR Gram-negative isolates were enterobacteria-producing ESBL, a mechanism of resistance that may be induced by the exposure to this class of antibiotics. [28] [29] [30] The other risk factor for MDR Gram-negative bacteremia found in the present study was being at a specific HSCT center. Interestingly, in that particular center no patient was exposed to third-generation cephalosporins. These findings suggest the local epidemiology in the whole hospital may strongly influence the rates of resistance at a particular HSCT unit.
We did not observe an association between infection owing to MDR Gram-negative bacteria and death. Conversely, having an underlying disease other than CML and undergoing a second transplant were strongly associated with a higher death rate by multivariate analysis. Both factors are expected to impact negatively on the immunity to increasing the risk for infection as well as organ toxicity. 31 This study has some limitations. Its main objective was to evaluate the epidemiology of bacteremia in the neutropenic phase of HSCT recipients in Brazil. To have a large number of centers that were representative of different regions, we designed a case report form with a limited number of variables. Therefore, some potential risk factors for MDR Gram-negative infection were not available, such as past history of hospitalization, use of antibiotics, as well as a profile of the rates of resistance in each hospital. Likewise, since we did not get information regarding changes in the empiric antibiotic regimen, we could not evaluate the impact of the use of appropriate antibiotic coverage and the outcome of MDR Gramnegative bacteremia. Furthermore, since we did not ask the investigators to send the isolates recovered from the blood cultures, we did not explore the possibility of clonality among the MDR Gram-negative isolates.
In conclusion, we observed a high rate of Gram-negative bacteremia among HSCT recipients from Brazil, and 37% of these isolates were MDR. Receipt of third-generation cephalosporins and being at one of the 12 centers were risk factors for the occurrence of these infections. These findings may have important clinical implications in decisions relating to prophylaxis and selection of the most appropriate regimen for empiric antibiotic treatment. Continuous surveillance is needed, especially in the centers with high incidences of resistance.
